MedPath

Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children

Registration Number
NCT02308527
Lead Sponsor
University of Birmingham
Brief Summary

The purpose of this study is to investigate whether Bevacizumab (an anti-VEGF monoclonal antibody) added to a backbone chemotherapy regimen (Temozolomide, Irinotecan-Temozolomide or Topotecan-Temozolomide) demonstrates activity in children with relapsed or refractory neuroblastoma. Also, to investigate whether the addition of Irinotecan or Topotecan to Temozolomide increases the activity of chemotherapy.The primary objective of the study is the best response (Complete Response or Partial Response) while trial treatment, within 18 or 24 weeks depending on the arm of the trial the participant is randomised to. Secondary endpoints are assessing the side effects, the length of time before progression (Progression Free Survival) and overall survival (OS).

This trial will address two important questions:

* does targeting blood vessel development using bevacizumab, (a monoclonal antibody against the Vascular Endothelial Growth Factor (VEGF)), add to the effect on a tumour when used with existing chemotherapy, compared to the effect of the existing chemotherapy alone (temozolomide)? NOTE- This question has been completed.

* does the addition of a second chemotherapy drug (irinotecan or topotecan) increase the effect on a tumour compared to the effect of one alone (temozolomide) NOTE - This question has been completed.

* does the addition of dinutuximab beta added to a backbone chemotherapy (temozolomide or temozolomide + topotecan) increase the effect of backbone alone.

Patients aged 1-21 years of age with relapsed or refractory high-risk neuroblastoma are randomised to one of two treatment arms: temozolomide-topotecan (TTo) or dinutuximab beta-temozolomide-topotecan (dBTTo). Temozolomide (T), irinotecan-temozolomide (IT), bevacizumab-T (BT), BIT (bevacizumab-IT), bevacizumab-temozolomide-topotecan (BTTo) and dinutuximab beta-temozolomide (dBT) are now closed to recruitment.

Detailed Description

This is an international open-label, randomised, multicentre phase II trial of temozolomide ± irinotecan, with or without bevacizumab, for the treatment of patients with relapsed or refractory neuroblastoma. The study will evaluate the safety and activity of these combinations.

Patients will be registered into the trial and randomised at the same time to one of the following two arms (approximately 30 patients per arm):

TTo: Temozolomide + Topotecan dBTTo: Dinuximab beta + Temozolomide + Topotecan

Arms which have now closed to recruitment:

dBT: Dinutuximab beat + Temozolomide Closed 28 \]Jan 2020 T: Temozolomide - Closed 28 Jan 2020 BT: Bevacizumab + Temozolomide - Closed 7 Feb 2019 IT: Irinotecan + Temozolomide - Closed 21 June 2018 BIT: Bevacizumab + Irinotecan + Temozolomide - Closed 21 June 2018 BTTo: Bevacizumab + Temozolomide + Topotecan - Closed 7 Feb 2019

Randomisation will be via a secure on-line computer-based system at the Cancer Research Clinical Trial Unit (CRCTU), University of Birmingham, United Kingdom (UK) and patients will be allocated in a 2:1 ratio. Minimisation will be used to ensure balance across the arms for the important prognostic factors as described by London et al. \[10\]: a) relapsed, refractory disease, b) early (\< 18 months), late relapse (≥18 months) and c) measurable versus evaluable disease (i.e. disease evaluated according to RECIST versus disease detectable only by MIBG scanning with or without bone marrow involvement as detected by local morphology) Patients will receive treatment for 6 courses, lasting 24 weeks.

Patients with a response (CR, PR) or stable disease (SD) while on the BEACON-Neuroblastoma trial will receive 6 cycles of trial treatment. If the patient has achieved a satisfactory response (i.e. CR, PR or SD) with acceptable toxicity, treatment may be extended beyond 6 cycles (up to 12 cycles) after discussion with the Sponsor and the Chief Investigator (CI).

In addition, patients randomised to TTo may recieve an optional regimen of dinutuximab beta + topotecan + cyclophosphamide (up to 6 cycles).

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
225
Inclusion Criteria

Not provided

Read More
Exclusion Criteria
  • Previous treatment with bevacizumab, temozolomide, irinotecan or any combination of these drugs
  • Known hypersensitivity to: Any study drug or component of the formulation, Chinese hamster ovary products or other recombinant human or humanised antibodies, Dacarbazine
  • Prior severe arterial thrombo-embolic events (e.g. cardiac ischemia, cerebral vascular accident, peripheral arterial thrombosis)
  • Any ongoing arterial thrombo-embolic events
  • Patient less than (at point of planned date of randomisation): 48 hours post bone marrow aspirate/trephine, 48 hours post central line insertion, Four weeks post major surgery, One week post core biopsy, Two weeks from prior chemotherapy, Six weeks from prior craniospinal radiotherapy or MIBG therapy and two weeks from radiotherapy to the tumour bed, Eight weeks from prior myeloablative therapy with haematopoietic stem cell rescue (autologous stem cell transplant), Three months from prior allogeneic stem cell transplant, 14 days or 5 half-lives (whichever occurs later) from last administration of an IMP in an IMP-trial, 6 months from presentation of lung haemorrhage/haemoptysis
  • Bleeding metastases (patients with CNS metastases can be enrolled as long as the metastases are not bleeding)
  • Invasion of major blood vessels
  • Use of enzyme inducing anticonvulsants within 72 hours of randomisation
  • History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e. in the absence of therapeutic anticoagulation)
  • History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess or active gastrointestinal bleeding within 6 months prior to study enrolment
  • Current chronic intestinal inflammatory disease/bowel obstruction
  • Intolerance to galactose and fructose, lactase deficiency, and/or defect of absorption of galactose and fructose
  • Pregnant or lactating patient
  • Any uncontrolled medical condition that poses an additional risk to the patient (i.e. haemoptysis, non-healing, bone fracture, wound/ulcer)
  • Low probability of treatment compliance
  • Any uncontrolled medical condition that poses an additional risk to the patient
  • Planned immunisation with live vaccine
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Arm && Interventions
GroupInterventionDescription
Bevacizumab + Irinotecan + TemozolomideIrinotecanBevacizumab Day 1 + Irinotecan Days 1-5 + Temozolomide Days 1-5 every 3 weeks
Bevacizumab + Temozolomide + TopotecanBevacizumabBevacizumab Day 1 and 15 + Temozolomide Days 1-5 + Topotecan Days 1-5 every 4 weeks
Bevacizumab + TemozolomideTemozolomideBevacizumab Day 1 and 15 + Temozolomide Days 1-5 every 4 weeks
Irinotecan + TemozolomideIrinotecanIrinotecan Days 1-5 + Temozolomide Days 1-5 every 3 weeks
Dinutuximab beta + Topotecan + CyclophosphamideDinutuximab BetaDinutuximab beta Days 1-7 + Topotecan Days 1-5 + Cyclophosphamide Days 1-5 every 4 weeks
Dinutuximab beta + Topotecan + CyclophosphamideCyclophosphamideDinutuximab beta Days 1-7 + Topotecan Days 1-5 + Cyclophosphamide Days 1-5 every 4 weeks
TemozolomideTemozolomideTemozolomide Days 1-5 every 4 weeks
Bevacizumab + TemozolomideBevacizumabBevacizumab Day 1 and 15 + Temozolomide Days 1-5 every 4 weeks
Irinotecan + TemozolomideTemozolomideIrinotecan Days 1-5 + Temozolomide Days 1-5 every 3 weeks
Bevacizumab + Irinotecan + TemozolomideBevacizumabBevacizumab Day 1 + Irinotecan Days 1-5 + Temozolomide Days 1-5 every 3 weeks
Bevacizumab + Irinotecan + TemozolomideTemozolomideBevacizumab Day 1 + Irinotecan Days 1-5 + Temozolomide Days 1-5 every 3 weeks
Temozolomide + TopotecanTopotecanTemozolomide Days 1-5+ Topotecan Days 1-5 every 4 weeks
Bevacizumab + Temozolomide + TopotecanTopotecanBevacizumab Day 1 and 15 + Temozolomide Days 1-5 + Topotecan Days 1-5 every 4 weeks
Temozolomide + TopotecanTemozolomideTemozolomide Days 1-5+ Topotecan Days 1-5 every 4 weeks
Dinutuximab beta + TemozolomideTemozolomideDinutuximab beta Days 1-7 + Temozolomide Days 1-5 every 4 weeks
Bevacizumab + Temozolomide + TopotecanTemozolomideBevacizumab Day 1 and 15 + Temozolomide Days 1-5 + Topotecan Days 1-5 every 4 weeks
Dinutuximab beta + TemozolomideDinutuximab BetaDinutuximab beta Days 1-7 + Temozolomide Days 1-5 every 4 weeks
Dinutuximab beta + Temozolomide + TopotecanTemozolomideDinutuximab beta Days 1-7 + Temozolomide Days 1-5 + Topotecan Days 1-5 every 4 weeks
Dinutuximab beta + Temozolomide + TopotecanTopotecanDinutuximab beta Days 1-7 + Temozolomide Days 1-5 + Topotecan Days 1-5 every 4 weeks
Dinutuximab beta + Temozolomide + TopotecanDinutuximab BetaDinutuximab beta Days 1-7 + Temozolomide Days 1-5 + Topotecan Days 1-5 every 4 weeks
Dinutuximab beta + Topotecan + CyclophosphamideTopotecanDinutuximab beta Days 1-7 + Topotecan Days 1-5 + Cyclophosphamide Days 1-5 every 4 weeks
Primary Outcome Measures
NameTimeMethod
Best response (Complete Response or Partial Response) while on trial treatment, within 18 or 24 weeks depending on the arm of the trial participant is randomised to.Within 18 or 24 weeks depending on the arm of the trial the participant is randomised to.

To test whether bevacizumab added to a backbone chemotherapy regimen (temozolomide, irinotecan-temozolomide or topotecan-temozolomide) demonstrates activity in children with relapsed or refractory neuroblastoma To test whether the addition of irinotecan to temozolomide increases the activity of chemotherapy in children with relapsed or refractory neuroblastoma

For the bevacizumab part 2 only; Progression-free survival (PFS)Assessment will be after 30 days after treatment or end of trial

Progression-free survival (PFS)

Secondary Outcome Measures
NameTimeMethod
To evaluate the safety of the regimensAssessment will be after 30 days after treatment or end of trial

Safety of the regimens: Event-free survival (EFS)

To evaluate the overall safety of the regimensAssessment will be after 30 days after treatment or end of trial

Safety of the regimens: Overall survival (OS)

To evaluate the toxicity of the regimensAssessment will be after 30 days after treatment or end of trial

Safety of the regimens: Incidence and severity of Adverse Events (AE)s

Trial Locations

Locations (10)

St Anna Children's Hospital and CCRI/Studies and Statistics

🇦🇹

Vienna, Austria

University Hospital Rigshospitalet

🇩🇰

Copenhagen, Denmark

Ospedale Pediatrico Bambino Gseu

🇮🇹

Rome, Italy

University Hospital

🇧🇪

Gent, Belgium

Hopital des Enfants

🇫🇷

Toulouse, France

Our Ladys Children's Hospital Dublin

🇮🇪

Dublin, Ireland

Natasha van Eijkelenburg

🇳🇱

Utrecht, Netherlands

Swiss Paediatric Oncology Group

🇨🇭

Bern, Switzerland

The Royal Marsden NHS Foundation Trust and Institute of Cancer Research

🇬🇧

Sutton, Surrey, United Kingdom

Instituto de Investigacion Sanitaria

🇪🇸

Valencia, Spain

© Copyright 2025. All Rights Reserved by MedPath